<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303614</url>
  </required_header>
  <id_info>
    <org_study_id>Hysterosalpingography-2010</org_study_id>
    <nct_id>NCT01303614</nct_id>
  </id_info>
  <brief_title>Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysterosalpingography Practice</brief_title>
  <acronym>HSG-2010</acronym>
  <official_title>Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysterosalpingography Practice: a Prospective Randomized Double Blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorci Sanitari de Terrassa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Consorci Sanitari de Terrassa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that Lidocaine-Prilocaine cream decrease pain
      during hysterosalpingography diagnostic practice.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain reduction in the performance of hysterosalpingography</measure>
    <time_frame>after hysterosalpingography and a month later</time_frame>
    <description>decrease in pain inmediately after the completion of hysterosalpingography and one month after completion of the diagnostic test by an analogue pain scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sense of discomfort experience during the procedure</measure>
    <time_frame>a month after hysterosalpingography</time_frame>
    <description>willingness to repeat the diagnostic technique</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gynecological Pathology</condition>
  <arm_group>
    <arm_group_label>Lidocaine-Prilocaine cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>purified water, ethylene glycol stearate, palm, palm stearate, polyethylene glycol, liquid paraffin, benzoic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine-Prilocaine cream</intervention_name>
    <description>Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.</description>
    <arm_group_label>Lidocaine-Prilocaine cream</arm_group_label>
    <other_name>EMLA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients that must perform a hysterosalpingography

          -  acceptance to participate in the study signed informed consent

        Exclusion Criteria:

          -  hypersensitivity or allergy to anesthetics

          -  refusal of the patient

          -  patients under age 18 years old and pregnant

          -  unbearable pain that involves other analgesic measures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baldomero Arnau Rivera, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consorci Sanitari de Terrassa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baldomero Arnau Rivera, MD, PhD</last_name>
    <phone>0034 937314138</phone>
    <email>barnau@cst.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baldomero Arnau Rivera</last_name>
      <phone>0034 937314138</phone>
      <email>barnau@cst.cat</email>
    </contact>
    <investigator>
      <last_name>Baldomero Arnau Rivera, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Baldomero Arnau Rivera</name_title>
    <organization>Consorci Sanitari de Terrassa</organization>
  </responsible_party>
  <keyword>hysterosalpingography</keyword>
  <keyword>prilocaine</keyword>
  <keyword>local anaesthetic</keyword>
  <keyword>pain relief</keyword>
  <keyword>gynecological pathology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>EMLA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

